IRVINE, Calif., March 6, 2024 /PRNewswire/ — Muse Microscopy Co., a wholly owned subsidiary of. smart health diagnosis companyhas developed a slide-less diagnostic imaging platform designed to transform the patient experience by providing the ability to generate digital tissue images within minutes and send them to pathologists for immediate reading. I am.

SmartHealth Diagnostics (PRNewsfoto/SmartHealth Diagnostics, Inc.)

Larry Dentis, president and director of Muse Microscopy, Inc., will be speaking. March 21st 10:45am, Track 3, at LSI USA '24. This presentation will focus on the future of direct-to-digital imaging using SmartPath MUSE Technology™ (SmartPath) equipment. As the leader in innovative his MUSE technology, we aim to revolutionize the patient and pathology experience by producing high quality direct digital images in minutes. SmartPath will be the first his MUSE-enabled technology imaging platform to be used in both the veterinary and human health commercial markets. Our ultimate strategic vision is to advance healthcare as the preferred data provider for AI applications.

For more information about the LSI USA '24 event, including registration details, please visit the official event website for Emerging Medtech Summit 2024 – Life Science Intelligence (

About Muse Microscopy, Inc.

Muse Microscopy, Inc. is a company specializing in microscopy applications using ultraviolet surface excitation (MUSE). We have developed his MUSE-enabled imaging system for diagnostic support in pathology, cytology, and research applications. Our commercial product, SmartPath MUSE Technology™ (SmartPath), is a slide-less, direct-to-digital imaging platform designed to transform the patient experience and provide healthcare professionals with rapid diagnostic information through digital imaging. is. For more information, please visit our website or find us on social media platforms such as Twitter, Facebook, and LinkedIn.

Forward-looking statements

The forward-looking statements in this press release are based on the Company's future expectations, projections and assumptions regarding matters that are not historical facts and are “forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.” This may apply to the description. “intended”, “anticipated”, “believe”, “continue”, “may”, “estimate”, “expect”, “intend”, “may”, Words such as “plan,” “may,” “anticipate,” “project,” “should,” “target,” “will,” “will” and similar expressions identify forward-looking statements. Although these forward-looking statements are intended to identify you, not all forward-looking statements contain these identifying words. Forward-looking statements relate to the future and are therefore subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those anticipated in the forward-looking statements. Accordingly, we caution you not to rely on these forward-looking statements. They are not statements of historical fact or guarantees of future performance.

The forward-looking statements we make in this document speak only as of the date on which they are made. There may be factors or events that occur from time to time that differ from actual results, and it is impossible to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Sision View original content to download multimedia: upcoming-emerging-medtech-summit-lsi-usa-24-in-dana-point-ca-302081075.html

SOURCE Muse Microscopy, Inc.

Source link